The National Institutes of Health today announced the start of an adaptive phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19.

NIH said the ACTIV-1 Immune Modulators trial will seek to determine if modulating immune responses that trigger so-called cytokine storms can reduce the need for ventilators and shorten hospital stays and whether the trialed therapeutics are able to restore balance to an overactive immune system.

Related News Articles

Headline
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce congue lorem nisl, ac dapibus dui vestibulum ut. Vivamus egestas at ipsum eget posuere.…
Headline
Moderna Inc. today announced that its mRNA-1273 vaccine candidate against COVID-19 is 94.5% effective, according to early data. The candidate is currently…
Headline
As of Nov. 6, about 60% of the nation’s retail pharmacies have agreed to participate in a federal program to administer COVID-19 vaccines at no cost to…
Perspective
“Don’t let perfect be the enemy of the good” is a quote credited to the French writer and thinker Voltaire. Although he died in 1778, that phrase is very…
Headline
To continue amplifying the important message of protecting against both the flu and COVID-19, AHA’s Wear A Mask and United Against the Flu campaigns today…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has released guidance on considerations for health…